JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-cou...
FDA Recall #D-0468-2023 — Class II — March 9, 2023
Product Description
JARDIANCE (Empagliflozin), 25 mg Tablets, packaged in a) 30-count (NDC0597-0153-30) and b) 90-count (NDC 0597-0153-90) bottles, Rx only, Marketed by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877 USA and Eli Lilly and Company Indianapolis, IN 46285 USA
Reason for Recall
Labeling: Label Mix-up
Recalling Firm
Boehringer Ingelheim Pharmaceuticals, Inc. — Ridgefield, CT
Classification
Class II — May cause temporary or medically reversible adverse health consequences.
Product Type
Drugs
Product Quantity
69,375 bottles
Distribution
Product was distributed nationwide within the United States and PR
Code Information
Lot #: a) and b) E61835, exp. date JUN 2025
Status
Terminated
Voluntary / Mandated
Voluntary: Firm initiated
What Should You Do?
Stop using this medication immediately and contact your pharmacist or doctor. Do not flush medications down the drain. Return the product to the place of purchase for a refund or replacement.